Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.3 SEK | +0.60% | +8.58% | +33.44% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.44% | 151M | C+ | ||
-2.63% | 103B | B+ | ||
+1.62% | 95.28B | B+ | ||
+1.46% | 22.15B | B | ||
-16.67% | 21.02B | B+ | ||
-8.58% | 18.15B | A- | ||
-38.74% | 16.73B | A- | ||
-13.21% | 16.05B | B | ||
+5.41% | 13.68B | C+ | ||
+33.57% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BINV Stock
- Ratings BioInvent International AB